Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and autoimmune diseases on people’s lives is why we’re here

Research and development

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

An immunotherapy platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ immunotherapy has the potential to treat many disease areas, including cancer.

Highlights

Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance ...

Read More
27 February 2025

Nykode Therapeutics reports Q4 2024 Financial Results

Read More
26 February 2025

Nykode Therapeutics – invitation to Q4 2024 financial results ...

Read More
14 February 2025

Nykode Therapeutics Announces Publication of Phase 2 VB-C-02 Data ...

Read More
08 January 2025

Nykode Therapeutics Presents New Data on Individualized Cancer Immunotherapy ...

Read More
04 December 2024

Nykode Therapeutics – Q3 2024 Financial Results – presentation

Read More
27 November 2024

Nykode Therapeutics reports Q3 2024 Financial Results

Read More
26 November 2024

Nykode Therapeutics – invitation to Q3 2024 financial results ...

Read More
20 November 2024

Nykode Therapeutics VB10.NEO update – presentation

Read More
08 November 2024